| Literature DB >> 28469101 |
Li Wang1, Xue-Ling Mei1.
Abstract
BACKGROUND: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening diseases with high mortality rates. This study was designed to analyze the pathogenic factors, clinical manifestations, complications, treatment, and prognosis of SJS/TEN and to explore the differences between surviving and deceased patients.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28469101 PMCID: PMC5421176 DOI: 10.4103/0366-6999.204929
Source DB: PubMed Journal: Chin Med J (Engl) ISSN: 0366-6999 Impact factor: 2.628
Demographic information of SJS/TEN patients
| Variables | Total ( | SJS ( | SJS/TEN overlap ( | TEN ( |
|---|---|---|---|---|
| Gender, | ||||
| Male | 40 (45.5) | 20 (41.7) | 19 (55.9) | 1 (16.7) |
| Female | 48 (54.5) | 28 (58.3) | 15 (44.1) | 5 (83.3) |
| Mean age (years), mean ± SD | 45 ± 18 | 48 ± 19 | 39 ± 15 | 49 ± 13 |
| Median hospital stay (days), median (inter quartile range) | 10 (7–15) | 10 (8–14) | 9 (7–14) | 37 (20–55) |
| History of drug allergy, | 6 (6.8) | 4 (8.3) | 2 (5.9) | 0 |
| Underlying disease, | 29 (33.0) | 16 (33.3) | 10 (29.4) | 3 (50.0) |
SJS: Stevens-Johnson syndrome; TEN: Toxic epidermal necrolysis; SD: Standard deviation.
Figure 1Age distribution among patients with Stevens-Johnson syndrome/toxic epidermal necrolysis (n = 88).
Figure 2Pathogenic factors of Stevens-Johnson syndrome/toxic epidermal necrolysis patients (n = 88).
Drugs that caused allergies in SJS/TEN patients
| Responsible drug(s) | Total ( | SJS ( | SJS/TEN overlap ( | TEN ( |
|---|---|---|---|---|
| Antibiotics | 24 (49.0) | 10 (55.6) | 12 (46.2) | 2 (40.0) |
| Levofloxacin | 3 (6.1) | 2 (11.1) | 1 (3.8) | 0 |
| Amoxicillin | 2 (4.1) | 0 | 1 (3.8) | 1 (20.0) |
| Azithromycin | 2 (4.1) | 1 (5.6) | 1 (3.8) | 0 |
| Clindamycin | 2 (4.1) | 1 (5.6) | 1 (3.8) | 0 |
| Cefdinir | 2 (4.1) | 2 (11.1) | 0 | 0 |
| Cefradine | 2 (4.1) | 0 | 2 (7.6) | 0 |
| Amoxicillin and clavulanate potassium | 1 (2.0) | 0 | 1 (3.8) | 0 |
| Cefoperazone sodium and sulbactam sodium | 1 (2.0) | 0 | 1 (3.8) | 0 |
| Cefuroxime axetil | 1 (2.0) | 0 | 1 (3.8) | 0 |
| Ceftizoxime | 1 (2.0) | 1 (5.6) | 0 | 0 |
| Latamoxef | 1 (2.0) | 1 (5.6) | 0 | 0 |
| Meropenem | 1 (2.0) | 0 | 1 (3.8) | 0 |
| Roxithromycin | 1 (2.0) | 0 | 1 (3.8) | 0 |
| Moxifloxacin hydrochloride | 1 (2.0) | 1 (5.6) | 0 | 0 |
| Etimicin sulfate | 1 (2.0) | 1 (5.6) | 0 | 0 |
| Mesylate pefloxacin | 1 (2.0) | 0 | 1 (3.8) | 0 |
| Norvancomycin | 1 (2.0) | 0 | 0 | 1 (20.0) |
| Anticonvulsant | 5 (10.2) | 0 | 4 (15.4) | 1 (20.0) |
| Carbamazepine | 2 (4.1) | 0 | 1 (3.8) | 1 (20.0) |
| Lamotrigine | 2 (4.1) | 0 | 2 (7.6) | 0 |
| Valproate | 1 (2.0) | 0 | 1 (3.8) | 0 |
| NSAID | 4 (8.2) | 1 (5.6) | 2 (7.6) | 1 (20.0) |
| Aspisol | 2 (4.1) | 1 (5.6) | 1 (3.8) | 0 |
| Acetaminophen | 2 (4.1) | 0 | 1 (3.8) | 1 (20.0) |
| Allopurinol | 1 (2.0) | 0 | 1 (3.8) | 0 |
| Omeprazole | 1 (2.0) | 1 (5.6) | 0 | 0 |
| Iohexol | 1 (2.0) | 1 (5.6) | 0 | 0 |
| Interferon | 1 (2.0) | 0 | 1 (3.8) | 0 |
| Compound medicine | 5 (10.2) | 2 (11.1) | 2 (7.6) | 1 (20.0) |
| Pseudoephedrine hydrochloride | 2 (4.1) | 1 (5.6) | 1 (3.8) | 0 |
| Dextromethorphan hydrobromide | 2 (4.1) | 1 (5.6) | 0 | 1 (20.0) |
| Anjiahuangmin | 1 (2.0) | 0 | 1 (3.8) | 0 |
| Traditional Chinese Medicine | 7 (14.3) | 3 (16.7) | 4 (15.4) | 0 |
| Xiaojinwan | 2 (4.1) | 0 | 2 (7.6) | 0 |
| Wei C Yinqiao Pian | 1 (2.0) | 1 (5.6) | 0 | 0 |
| Sanhuang Pian | 1 (2.0) | 1 (5.6) | 0 | 0 |
| Zhengqingfengtongning | 1 (2.0) | 1 (5.6) | 0 | 0 |
| Herbal medicine | 2 (4.1) | 0 | 2 (7.6) | 0 |
The data was presented by n (%). SJS: Stevens-Johnson syndrome; TEN: Toxic epidermal necrolysis; NSAID: Nonsteroidal anti-inflammatory drug.
Clinical manifestations, visceral damage, and mortalities among SJS/TEN patients
| Variables | Total ( | SJS ( | SJS/TEN overlap ( | TEN ( |
|---|---|---|---|---|
| Fever, | 62 (70.5) | 30 (62.5) | 26 (76.5) | 6 (100.0) |
| Leukocytosis, | 35 (39.8) | 16 (33.3) | 16 (47.1) | 3 (50.0) |
| % BSA, mean ± SD | 12.5 ± 12.5 | 5.2 ± 2.2 | 16.6 ± 6.6 | 50.0 ± 10.0 |
| Organ involvement, | ||||
| Hepatitis | 32 (36.4) | 17 (35.4) | 12 (35.3) | 3 (50.0) |
| Renal dysfunction | 8 (9.1) | 3 (6.3) | 3 (8.8) | 2 (33.3) |
| Gastrointestinal | 11 (12.5) | 3 (6.3) | 4 (11.8) | 4 (66.7) |
| Respiratory | 10 (11.4) | 3 (6.3) | 3 (8.8) | 4 (66.7) |
| Encephalopathy | 2 (2.3) | 0 | 1 (2.9) | 1 (16.7) |
| Myocarditis | 5 (5.7) | 1 (2.1) | 3 (8.8) | 1 (16.7) |
| DIC | 7 (8.0) | 3 (6.3) | 2 (5.9) | 2 (33.3) |
| Mortality, | 6 (6.8) | 2 (4.2) | 2 (5.9) | 2 (33.3) |
SJS: Stevens-Johnson syndrome; TEN: Toxic epidermal necrolysis; BSA: Body surface area; SD: Standard deviation; DIC: Disseminated intravenous coagulation.
Univariate analysis of the clinical characteristics of the survival and deceased groups (n = 88)
| Variables | Survived group (%) | Deceased group (%) | ||
|---|---|---|---|---|
| Age >70 years | 8.5 | 16.7 | 0.447 | 0.504 |
| Male gender | 46.3 | 33.3 | 0.382 | 0.537 |
| Recent pathological history | ||||
| Cancer | 0.0 | 33.3 | 27.969 | <0.001 |
| Renal disease | 1.2 | 16.7 | 6.006 | 0.014 |
| Liver disease | 1.2 | 16.7 | 6.006 | 0.014 |
| Prior infections | 41.5 | 50.0 | 0.167 | 0.683 |
| Autoimmune diseases | 3.7 | 33.3 | 9.187 | 0.002 |
| Diabetes | 9.8 | 33.3 | 3.086 | 0.079 |
| Eye involvement | 32.9 | 66.7 | 2.789 | 0.095 |
| Oral mucosa involvement | 36.6 | 66.7 | 2.134 | 0.144 |
| Genital involvement | 22.0 | 50.0 | 2.421 | 0.120 |
| Involvement of three mucosal areas | 14.6 | 50.0 | 4.945 | 0.026 |
| Heart rate >100 beats/min | 12.2 | 50.0 | 6.347 | 0.012 |
| WBC >10.0×109/L | 41.5 | 50.0 | 0.167 | 0.683 |
| BSA involvement >20% | 13.4 | 50.0 | 5.594 | 0.018 |
| Liver involvement | 30.5 | 100.0 | 11.839 | 0.001 |
| BUN >10 mg/dl | 2.4 | 66.7 | 36.302 | <0.001 |
| Serum bicarbonate <20 mEq/L | 2.4 | 50.0 | 23.599 | <0.001 |
| Steroid treatment | 42.7 | 100.0 | 7.381 | 0.007 |
| Antibiotics use | 46.3 | 83.3 | 3.062 | 0.080 |
| Infection | 46.3 | 83.3 | 3.062 | 0.080 |
| SCORTEN >2 | 8.5 | 83.3 | 37.148 | <0.001 |
WBC: White blood cell; BSA: Body surface area; BUN: Blood urea nitrogen; SCORTEN: Toxic epidermal necrolysis specific severity of illness score.
Analysis of the six deceased cases among patients with SJS/TEN
| Case number | Disease | Age | Sex | Underlying disease | Causative drugs | Indication for drug therapy | Maximum skin detachment (%) | Clinical course of the skin lesion | Severe complications and cause of death | Maximum doses of corticosteroids and other therapies | SCORTEN | Time to death |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | SJS | 62 | Female | Hemophagocytic syndrome, T cell lymphoma | NA | NA | 8 | Improved | Lung infection, liver/kidney failure | mPSL 40 mg/d | 4 | 14 |
| 2 | SJS | 62 | Female | Systemic lupus erythematosus | Imipenem, vancomycin | Lung infection | 5 | No change | Lung infection, respiratory failure | DXM 10 mg/d | 2 | 6 |
| 3 | SJS/TEN overlap | 83 | Male | Lung cancer | Meropenem | Lung infection | 22 | Improved | Lung infection, respiratory failure, DIC | mPSL 80 mg/d, IVIG 20 g/day | 5 | 12 |
| 4 | SJS/TEN overlap | 66 | Male | Mesenteric venous thrombosis with intestinal necrosis | Cefoperazone sodium and sulbactam sodium | Peritonitis | 18 | Healed | Peritonitis, bacterial sepsis, fungal sepsis | mPSL 80 mg/d, IVIG 20 g/day | 3 | 30 |
| 5 | TEN | 45 | Female | Sjögren’s disease, primary biliary cirrhosis | Norvancomycin | Lung infection | 65 | Improved | Lung infection, respiratory failure | mPSL 120 mg/d, IVIG 20 g/day | 4 | 10 |
| 6 | TEN | 67 | Female | Type II diabetes | Amoxicillin | Upper respiratory tract infection | 70 | Healed | Pulmonary embolism resulting from the detached vein thrombosis in lower limbs | mPSL 160 mg/d, IVIG 20 g/day | 3 | 46 |
Time to death: Time between the onset of eruption and death. SJS: Stevens–Johnson syndrome; mPSL: Methylprednisolone; DXM: Dexamethasone; IVIG: Intravenous immunoglobulin; DIC: Disseminated intravenous coagulation; TEN: Toxic epidermal necrolysis; SCORTEN: Toxic epidermal necrolysis specific severity of illness score; NA: Not available.